Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics
Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics have?
Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics has 20 citations in the OpenAlex counts ScholarIQ stores.
When was Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics published?
Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics has 2017 year in the ScholarIQ index.
What is the open-access status of Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics?
Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics has closed oa status in the ScholarIQ index.
What is the DOI of Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics?
The DOI for Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics is on the source record.
What is the PMID of Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics?
The PMID for Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics is on the source record.
What is the OpenAlex record for Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics?
The OpenAlex for Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics is on the source record.